CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced the completion of its previously announced acquisition of Retina Consultants of America, a leading management services organization (MSO) of retina specialists.
Cencora has acquired an interest in RCA of approximately 85%, with certain RCA physicians and members of the management team retaining a minority equity interest in the company. After giving effect to the equity rollover, a cash capitalization of RCA that Cencora has made, the payment of transaction fees and expenses and the repayment of debt, Cencora’s cash outlay at closing was $4.4 billion, which amount is subject to a customary post-closing purchase price adjustment. The acquisition allows Cencora to build on its leadership in specialty, expand its MSO solutions and drive differentiated value for stakeholders, including physicians and patients.
Fiscal Year 2025 Expectations
The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available or cannot be reasonably estimated.
Fiscal Year 2025 Expectations on an Adjusted (non-GAAP) Basis
Cencora has updated its fiscal year 2025 financial guidance to reflect the expected contribution from the closing of the RCA acquisition and also continued momentum in the U.S. Healthcare Solutions reportable segment. The Company now expects adjusted diluted earnings per share (EPS) to be in the range of $15.15 to $15.45, raised from the previous range of $14.80 to $15.10.
Please refer to the Supplemental Information Regarding Non-GAAP Financial Measures below.
About Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. Cencora partners with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on Cencora for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Cencora’s 46,000+ worldwide team members contribute to positive health outcomes through the power of Cencora’s purpose: Cencora is united in its responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $290 billion in annual revenue. Learn more at investor.cencora.com.
